Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autogene cevumeran + atezolizumab + fluorouracil + leucovorin + irinotecan + oxaliplatin
- Development stage
- Unknown
- Lead developer
- BioNTech
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
BNT122 + atezolizumab + fluorouracil + leucovorin + irinotecan + oxaliplatin is an investigational combination immunotherapy and chemotherapy regimen being evaluated for the adjuvant treatment of resected pancreatic ductal adenocarcinoma (PDAC). The regimen is built around autogene cevumeran (BNT122; RO7198457), an individualized, mRNA-based neoantigen cancer vaccine (iNeST) co-developed by BioNTech and Genentech. Autogene cevumeran is a uridine mRNA-lipoplex designed to encode up to 20 patient-specific tumor neoantigens to stimulate a targeted T-cell response. This vaccine is combined with atezolizumab (Tecentriq), an anti-PD-L1 monoclonal antibody checkpoint inhibitor, and mFOLFIRINOX, a standard cytotoxic chemotherapy regimen consisting of 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin. The combination is currently being evaluated in the randomized Phase II IMCODE003 trial (NCT05968326) sponsored by Genentech, comparing the regimen to mFOLFIRINOX alone.
- Other names
- BNT122 + Tecentriq + mFOLFIRINOXBNT122 + atezolizumab + fluorouracil + leucovorin + irinotecan + oxaliplatinBNT122 + atezolizumab + mFOLFIRINOXRG6180 + atezolizumab + fluorouracil + leucovorin + irinotecan + oxaliplatinRO7198457 + atezolizumab + fluorouracil + leucovorin + irinotecan + oxaliplatinautogene cevumeran + Tecentriq + mFOLFIRINOXautogene cevumeran + atezolizumab + mFOLFIRINOX
02
Targets
DNATOP1 (DNA Topoisomerase I)CD274 (Programmed cell death protein 1 ligand 1)TS (Thymidylate synthase)
Beyond the preview
Go deeper on autogene cevumeran + atezolizumab + fluorouracil + leucovorin + irinotecan + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autogene cevumeran + atezolizumab + fluorouracil + leucovorin + irinotecan + oxaliplatin.